Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
| ▸ | CD69 | Q07108 | 1/20 | 0.33 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MGAM | O43451 | 1/20 | 0.33 |
| ▸ | SI | P14410 | 1/20 | 0.33 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1473043 | 0.79 | ADRA2A (0.35) | HSD17B10LMNASMN1; SMN2ADRA2AADRA2B | |
| SCHEMBL8161008 | 0.78 | POLB (0.39) | HSD17B10LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL1473328 | 0.76 | CD69 (0.48) | HSD17B10ADRA2AADRA2BADRA2CCD69 | |
| SCHEMBL6578128 | 0.74 | LMNA (0.47) | HSD17B10LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL13987037 | 0.72 | TLR4 (0.49) | ELANECD69TLR4 | |
| SCHEMBL9255038 | 0.72 | CYP2D6 (0.43) | HSD17B10LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL14424604 | 0.72 | POLB (0.36) | HSD17B10LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL3595767 | 0.71 | ALDH1A1 (0.41) | LMNASMN1; SMN2ADRA2AADRA2BADRA2C | |
| SCHEMBL25317242 | 0.70 | ACHE (0.50) | HSD17B10LMNASMN1; SMN2PTGS1PTGS2 | |
| SCHEMBL5086988 | 0.70 | MAPT (0.47) | LMNASMN1; SMN2MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8466212-B2 | Process for preparing dental materials having low polymerization shrinkage | IVOCLAR VIVADENT AG (LI) | 2013-06-18 | — | — | US | disclosed |
| EP-1970042-B1 | Use of polymerisable Calix[n]arenes as dental materials | IVOCLAR VIVADENT AG (LI) | 2011-03-02 | — | — | EP | disclosed |
| US-20100311863-A1 | PROCESS FOR PREPARING DENTAL MATERIALS HAVING LOW POLYMERIZATION SHRINKAGE | HERAEUS KULZER GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| EP-1970042-A2 | Dental materials with low polymerisation shrinkage | Ivoclar Vivadent AG (LI) | 2008-09-17 | — | — | EP | disclosed |
| US-20080058443-A1 | Dental materials having low polymerization shrinkage | HERAEUS KULZER GMBH (DE) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058443-A1 | Dental materials having low polymerization shrinkage | CALD1, RCC1, ITGA1 | HSD17B10 3006/4885LMNA 555/4885SMN1; SMN2 4565/4885 |
| US-20100311863-A1 | PROCESS FOR PREPARING DENTAL MATERIALS HAVING LOW POLYMERIZATION SHRINKAGE | CALD1, ITGA1, RCC1 | HSD17B10 2988/4885LMNA 335/4885SMN1; SMN2 4415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.